Thyrotropin Receptor Antibody Levels at Diagnosis and after Thionamide Course Predict Graves' Disease Relapse

Thyroid

Volumn 26, Issue 8, 2016, Pages 1004-1009

  Tun, Nyo Nyo Z ^a   Beckett, Geoff ^a   Zammitt, Nicola N ^a   Strachan, Mark W J ^a   Seckl, Jonathan R ^a   Gibb, Fraser W ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; THIONAMIDE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; ANTITHYROID AGENT; AUTOANTIBODY; CARBIMAZOLE; PROPYLTHIOURACIL; THYROTROPIN RECEPTOR;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; DRUG WITHDRAWAL; EUTHYROIDISM; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; THYROID FUNCTION TEST; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT WITHDRAWAL; AGE; BLOOD; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS;

ADULT; AGE FACTORS; ANTITHYROID AGENTS; AUTOANTIBODIES; CARBIMAZOLE; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPYLTHIOURACIL; RECEPTORS, THYROTROPIN; RECURRENCE; THYROXINE; TRIIODOTHYRONINE;

EID: 84982938656     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2016.0017     Document Type: Article

References (21)

1. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg, P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2012 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593-646.
2. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M 2008 Long-term followup of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866-872.
3. Solomon BL, Evaul JE, Burman KD, Wartofsky L 1987 Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med 107:510-512.
4. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7:369-375.
5. Okamoto Y, Tanigawa S-i, Ishikawa K, Hamada N 2006 TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocrine J 53:467-472.
6. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR 2002 Does smoking increase relapse rates in Graves' disease? J Endocrinol Invest 25:152-157.
7. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA 2000 Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85:1038-1042.
8. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA 2007 Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocrine J 54:713-720.
9. Barbesino G, Tomer Y. 2013 Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98:2247-2255.
10. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS 2010 Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev CD003420.
11. Syme NR, Toft AD, Stoddart M, Beckett GJ 2011 Clinical performance of the Roche cobas e411 automated assay system for thyrotropin-receptor antibodies for the diagnosis of Graves' disease. Ann Clin Biochem 48:471-473.
12. Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, van Helden J, Inomata K, Jarausch J, Kratzsch J, Mann K, Miyazaki N, Navarro Moreno MA, Murakami T, Roth HJ, Noh HJ, Scherbaum WA, Schott M 2009 Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta 401:84-89.
13. Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA 2013 Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98:1869-1882.
14. Liu C, Hermsen D, Domberg J, Graeber C, Hautzel H, Duan Y, Xu KF, Liu CP, Mao XD, Cupisti K, Scherbaum WA, Schott M 2008 Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Horm Metab Res 40:479-483.
15. Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G 2012 TSHR-LH/ CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab 97:E1080-E1087.
16. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U 2002 Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 146:173-177.
17. Feldt-Rasmussen U, Schleusener H, Carayon P 1994 Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78:98-102.
18. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J 2004 Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 36:92-96.
19. Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, Esser J, Morgenthaler NG 2007 Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607-612.
20. Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L 2008 The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93:3985-3988.
21. Vanderpump MP, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K, Franklyn JA, British Thyroid Association UK Iodine Survey Group 2011 Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 377:2007-2012.